NCT00175955

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (planned)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Conditions

• Dyskinesia, Medication-induced

Interventions

Type	Name	Description
DRUG	Levetiracetam

Timeline

• Start date: 2005-05-01
• Primary completion: 2005-12-01
• Completion: 2005-12-01
• First posted: 2005-09-15
• Last updated: 2013-12-06

Locations

7 sites across 2 countries: Belgium, Bulgaria